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BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell
cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral
resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy.
METHODS: Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical
variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of
disease. The primary endpoint was death from prostate cancer.
RESULTS: In univariate analysis (n¼ 349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), Po109)
for a one-unit increase in CCP score. The CCP score was only weakly correlated with standard prognostic factors and in a
multivariate analysis, CCP score dominated (HR for one-unit increase¼ 1.65, 95% CI (1.31, 2.09), P¼ 3 105), with Gleason score
(P¼ 5 104) and prostate-specific antigen (PSA) (P¼ 0.017) providing significant additional contributions.
CONCLUSION: For conservatively managed patients, the CCP score is the strongest independent predictor of cancer death outcome
yet described and may prove valuable in managing clinically localised prostate cancer.
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Prostate cancer is now the most common cancer in men in the
developed world, especially when prostate-specific antigen (PSA)
testing is used (Jemal et al, 2009; Ferlay et al, 2010). Its natural
history is highly variable and difficult to predict. Some men have
indolent disease that can be safely followed without immediate
treatment, whereas others have an aggressive cancer and benefit
from immediate intervention. Accurate prediction of disease
behaviour is critical because radical treatment is associated with
high morbidity. The problems associated with an uncertain
prognosis have been exacerbated by the introduction of PSA
testing in some countries, leading to an increase in reported
incidence but having at most a small effect on mortality rates
(Lu-Yao and Greenberg, 1994; Chou et al, 2011). Autopsy series
indicate a very high prevalence of asymptomatic prostate cancer in
70-year-old men dying from other causes (28% (Breslow et al,
1977), 25% (Billis, 1986), 64% (Sakr et al, 1994), 33% (Sa´nchez-
Chapado et al, 2003), 50% (Soos et al, 2005)), which is more than
five times higher than the lifetime risk of dying from prostate
cancer in the western world, indicating that intensive screening
increases the detection of indolent disease (Brawley, 1997;
Etzioni et al, 2002).
Clinical variables including Gleason score, tumour stage, and
PSA concentration have been used at the time of diagnosis to
predict disease outcome. However, predictions based on these
variables are far from perfect, leading to considerable uncertainty
among physicians and patients about the best course for initial
treatment. In a recent study, we showed that a cell cycle
progression (CCP) score added a substantial amount of prognostic
information regarding death from prostate cancer in a cohort of
men with clinically localised disease diagnosed by transurethral
resection of the prostate (TURP) and managed conser-
vatively (Cuzick et al, 2011). Similar results were also seen for
biochemical progression in men who were treated by radical
prostatectomy.
However, to make a significant impact in the clinic, prognostic
markers such as the CCP score, must demonstrate clinical utility
when generated from diagnostic needle biopsies. In this study, we
report on the ability of the CCP score to predict death from
prostate cancer, when measured in needle biopsy material,
in a cohort of men with clinically localised disease diagnosed by
a needle biopsy and managed conservatively.
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PATIENTS AND METHODS
Patients
Potential cases of adenocarcinoma of the prostate were identified
from six cancer registries in Great Britain. Case notes from
collaborating hospitals were reviewed, and full details of these
patients have been reported (Cuzick et al, 2006, 2011). Men were
included in this study if they had conservatively treated clinically
localised prostate cancer, which was diagnosed by use of needle
biopsy between 1990 and 1996 (inclusively), were younger than 76
years at the time of diagnosis, and had a baseline PSA
measurement. Patients treated with radical prostatectomy or
radiation therapy, within the first 6 months after diagnosis, or
who died or showed evidence of metastatic disease within 6
months of diagnosis were excluded. Men who had hormone
therapy before the diagnostic biopsy were also excluded. Original
histological specimens from the diagnostic procedure were
requested, collected, and centrally reviewed by a panel of expert
urological pathologists to confirm the diagnosis of adenocarcinoma
and, where necessary, to reassign Gleason scores by use of a
contemporary and consistent interpretation of the Gleason scoring
system (Montironi et al, 2005). Follow-up was conducted through
the cancer registries and the last review took place in December
2006. For the purpose of establishing study maturity, follow-up
was computed as potential follow-up, commencing at date of
diagnosis and is reported for all patients as if alive at the end of the
study. Deaths were divided into those from prostate cancer and
those from other causes, according to World Health Organization
standardised criteria (WHO, 2010). National ethics approval was
obtained from the Northern Multicentre Research Ethics Commit-
tee, followed by local ethics committee approval at each of the
collaborating hospitals.
Sample preparation and real-time PCR
Approximately 2–4mm lengths of tumour, identified by review of
the corresponding H&E section, were excised from the needle biopsy
blocks using scalpel blades spaced at 4 and 2mm, as previously
described (Jhavar et al, 2005). The amount dissected was determined
both by the length of cancer available in the core, and also to enable
preservation of any remaining cancer tissue for tissue micro array
studies. Paraffin was removed by xylene treatment and the tumour
sample was washed with ethanol. Samples were then digested
overnight with proteinase K digestion at 551C.
Total RNA was extracted with miRNeasy (Qiagen, Valencia, CA,
USA) as described by the manufacturer (with the exception of the
extended proteinase K digestion).
Total RNA was treated with DNase I (Sigma-Aldrich, St Louis,
MO, USA) before cDNA synthesis. We used the High-capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) to
convert total RNA into single-strand cDNA as described by the
manufacturer. Ideally, at least 200 ng of RNA was required for the
reverse transcription, but use of smaller input amounts was also
successful. The quality of the RNA was not ideal because of sample
age. To generate a CCP score, essentially all 15 housekeeping genes
and at least 21 of the 31 CCP genes had to be amplified. We
attempted to generate a CCP score from every sample. For some of
the samples, some genes did not amplify, indicating that the RNA
quality was too poor to obtain a score. Before measurement of gene
expression, the cDNA was preamplified in a pooled reaction
containing TaqMan assays (Applied Biosystems). Preamplification
reaction conditions were 14 cycles at 951C for 15 s and 601C for
4min. The first cycle also included 10min incubation at 951C. The
amplification reaction was diluted 1 : 20 with the 1 Tris-EDTA
buffer before it was loaded on TaqMan Low Density arrays
(Applied Biosystems) to assess the amplified genes. Expression
data were recorded as a threshold cycle value, the PCR cycle at
which the fluorescence intensity exceeded a predefined threshold.
Cell cycle progression score
We attempted to compute the CCP score for each individual, where
adequate material was available. A total of 31 predefined CCP
genes and 15 housekeeper genes were amplified on one TaqMan
Low Density array. Full details have been published (Cuzick et al,
2011) and also given in Supplementary Tables ST2 and ST3. The
values of each of three replicates of each of the 31 CCP genes were
normalised by subtraction of the average of up to 15 non-failed
housekeeper genes for that replicate.
Statistical analysis
Survival analysis was carried out with a Cox proportional hazards
model. The primary endpoint was time to death from prostate
cancer. Observations were censored on the date of last follow-up,
or at death from other causes. Covariates evaluated were: centrally
reviewed Gleason primary grade and score, baseline PSA value,
clinical stage, extent of disease (proportion of positive cores), age
at diagnosis, Ki-67 immunohistochemistry, and initial treatment
(no initial treatment or early hormone management).
All PSA values after treatment with hormones or orchiectomy
or within 3 weeks after a surgical procedure to the prostate were
excluded. Baseline PSA concentration was defined as the last
prediagnostic PSA measurement within 6 months before diagnosis.
If no such PSA value was available, we took the first post-diagnostic
PSA within 6 months; failing that, the prediagnostic PSA taken
closest to the date of diagnosis was used. The analysis set and a
complete analysis plan were pre specified and all CCP scores were
assigned, before the clinical and outcome data were unmasked.
The concentration of PSA was modelled as the natural logarithm
of (1þ PSA (ngml1)). Patients with PSA values greater than
100 ngml1 were excluded as likely to be metastatic disease.
For simplicity, Gleason scores were grouped into less than 7, equal
to 7, and greater than 7. Little difference was seen between Gleason
3þ 4 and 4þ 3, so they were combined (Cuzick et al, 2006).
All P-values were two-sided and 95% CIs and P-values were based
on w2 statistics with 1 degree of freedom, unless otherwise indicated,
obtained from partial likelihoods of proportional hazards models.
The main assessment was a univariate analysis of the association
between death from prostate cancer and CCP score. A further
predefined assessment of the added prognostic information after
adjustment for the baseline variables was also undertaken. This
later effect was measured by use of the decrease in the likelihood
ratio w2, when the CCP score was omitted from a model containing
it and the other relevant baseline clinicopathological variables.
A multivariate Cox proportional hazards model was used for this
purpose and to create a combined score based on the major
clinical variables and the CCP score. For the primary analysis, the
CCP score was evaluated as a linear term. We used a forward
stepwise regression in which a new variable was added only if it
had a P-value of less than 0.05. Exploratory analyses included
adding a quadratic term for the CCP score to further evaluate the
shape of the dose-response curve for predicting death from
prostate cancer, testing for proportional hazards, evaluating
predictive value in years 0–5 and 5þ separately, and testing for
interactions of the CCP score with individual covariates. Statistical
analyses were carried out with STATA (version 11.2; StataCorp,
College Station, TX, USA) and R (version 2.12 ; The R Foundation
for Statistical Computing, Vienna, Austria, http://www.R-project.
org/).
RESULTS
The assembly of the cohort is shown in the Supplementary Figure
SF1. Out of 776 patients diagnosed by needle biopsy and for which
a section was available to review histology, needle biopsies were
retrieved from 527, and of them, 442 had adequate biopsy material
to assay. Of these, 349 (79%) produced a CCP score and
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had complete baseline and follow-up information. The median
potential follow-up time was 11.8 years. A total of 90 deaths from
prostate cancer occurred within the 2799 person-years of actual
follow-up. The demographic and tumour characteristics of these
men are shown in Supplementary Table ST1 and compared with
the entire needle cohort. No factor was significantly different at the
1% level, indicating that this was a representative sample.
The median CCP score was 1.03 and the interquartile range was
from 0.41 to 1.74. In the primary univariate analyses, a one-unit
increase in CCP score was associated with a 2.02-fold increase in
the hazard of dying from prostate cancer. This was highly
significant (w2¼ 37.6, P¼ 8.6 1010, 95% CI (1.62, 2.53)). This
corresponds to a hazard ratio (HR) of 2.56 (95% CI 1.90, 3.45), for
a change from the 25th to 75th percentile of the CCP score
distribution (Table 1). The 10-year death rate from prostate cancer
for one-unit groups of the CCP score is shown in Figure 1. For
those with a score less than 0, the rate was 19.3% and increased to
19.8%, 21.1%, 48.2%, and 74.9% for CCP score groups (0–1, 1–2,
2–3, and 43, respectively). Assuming a linear relationship, the
10-year death rate from prostate cancer, estimated from CCP score
alone, is shown in Supplementary Figure SF2. The CCP score was
only weakly correlated with other known prognostic factors;
Gleason: r¼ 0.37; PSA: r¼ 0.14; extent of disease: r¼ 0.28.
In the pre-planned multivariate analyses, extent of disease, age,
clinical stage, and use of hormones were not statistically significant
and only CCP score, Gleason grade, and PSA remained in the final
model (Table 1). Ki67 was included in the multivariate analysis,
but was not significant (results not shown). The HR for a one-unit
change in the CCP score in the multivariate model was 1.65 (95%
CI 1.31, 2.09) w2¼ 17.7, P¼ 3 105), and it was a stronger
prognostic factor than either Gleason grade or PSA. This
corresponds to a HR of 1.96 (95% CI 1.43, 2.68), for a change
from the 25th to 75th percentile of the CCP score distribution. The
best linear predictor combining these variables was
Combined Score ¼ð0:50CCPþ 0:49ðGleason ¼ 7Þ
þ 1:14ðGleason47Þ þ 0:32logð1þ PSAÞÞ
In exploratory analyses, we found that adding a quadratic term for
the CCP score in the multivariate analysis was statistically
significant (P¼ 0.008) and with this extra term, CCP score was
even more significant (w2 (2.d.f)¼ 24.8, P¼ 4 106) than CCP
score alone (P¼ 3 105). There was also evidence of a strong
effect of the CCP score in predicting death in the first 5 years of
follow-up (multivariate HR¼ 2.14, (95% CI 1.55, 2.95) w2¼ 22,
P¼ 3 106) with a much lesser effect thereafter (multivariate
HR¼ 1.27, (95% CI 0.92, 1.75) w2¼ 2.1, P¼ 0.15). Both of these
observations can be explained by the strong effect of high CCP
score on early deaths. Further data are needed to confirm these
observations, regarding the apparent super-linear form of the
prognostic value of the CCP score and the duration of its impact.
The 10-year risk of death from prostate cancer across the range of
this combined score is shown in Figure 2.
A forest plot of the prognostic value of the CCP score by Gleason
grade and PSA level is shown in Figure 3. Little variation was seen
except for a non-significant trend toward higher HRs for the CCP score
in higher Gleason grades (P-value for heterogeneity¼ 0.13, Q Statistic).
Table 1 Univariate and multivariate analysis for death from prostate cancer
Univariate analysis Multivariate analysis
Variable N v2 (1 df)
Hazard ratio
(95% CI) P-value N v2 (1 df)
Hazard ratioa
(95% CI) P-value
CCP score 349 37.6 2.02 (1.62, 2.53) 8.6 1010 349 17.7 1.65 (1.31, 2.09) 2.6 105
Gleason score
o7 106 36.4 0.46 (0.25, 0.86) 1.6 109 106 12.1 0.61 (0.32, 1.16) 5.0 104
7 152 1 (ref) 152 1 (ref)
47 91 2.70 (1.72, 4.23) 91 1.90 (1.18, 3.07)
log (1+PSA) (ngml1) 349 16.8 1.70 (1.31, 2.20) 4.2 105 349 5.7 1.37 (1.05, 1.79) 0.017
Extent of diseaseb
o50% 69 14.1 0.50 (0.22, 1.12) 0.0002
50–o100% 106 1 (ref)
100% 160 1.66 (1.01, 2.73)
Age at diagnosis (years) 349 0.05 1.00 (0.96, 1.04) 0.82
Clinical stage
T1 38 3.72 0.75 (0.32, 1.75) 0.054
T2 106 1 (ref)
T3 43 1.74 (0.90, 3.38)
Hormone use
No 200 10.2 1 (ref) 0.001
Yes 149 1.97 (1.30, 2.98)
Abbreviations: w2¼ chi-square; df¼ degrees of freedom; CI¼ confidence interval; ref¼ reference category; PSA¼ prostate-specific antigen. aGleason score assessed with 2df for
computing the hazard ratios in the multivariate analysis. bProportion of positive cores.
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Figure 1 Kaplan–Meier estimates of prostate cancer death according to
CCP score. Different categories of CCP score are shown by different
coloured lines: red, CCP score43 (n¼ 16), orange, 2oCCP score p3
(n¼ 50); blue, 1oCCP score p2 (n¼ 114); purple, 0oCCP score p1
(n¼ 133); green, CCP score p0 (n¼ 36).
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To illustrate how the addition of CCP score changes patient prognosis,
we compared the prediction of 10-year prostate cancer death rate based
on the combined score to the prediction obtained from using only PSA
and Gleason score (Figure 4). A useful discrimination is seen within
each Gleason score, and adding both CCP score and PSA was seen to
provide more discrimination than adding PSA alone.
DISCUSSION
These results confirm our previous findings (Cuzick et al, 2011) on
the prognostic value of the CCP score measured after radical
surgery and in TURP specimens, and extend them to the clinical
situation where the CCP score is generated from tissue obtained
from diagnostic needle biopsies. In this clinical setting, CCP score
was highly prognostic, and provided more information than either
Gleason score or PSA. In addition, because it was only weakly
correlated with other clinical variables it provides important
independent information that cannot be obtained otherwise.
Although this cohort does not reflect contemporary treatment of
prostate cancer, in that a much greater proportion of patients were
managed conservatively, it does have the advantage of providing
information on the cancer death rates in this wider population and
thus facilitates the ability to identify which patients will do well or
poorly with conservative management in a broader context than
would be possible with contemporary cohorts. To the best of our
knowledge, this is the first study in any cancer to evaluate the
prognostic value of an mRNA-based test in needle biopsies. Needle
biopsies sample only a small portion of the tumour and provide a
limited amount of tissue from which to generate molecular data.
Both limitations, tumour sampling and tissue amount, could have
adversely affected the ability of this molecular assay to predict
disease outcome at diagnosis. However, we found that CCP score
generated from needle biopsies predicted prostate cancer death
more accurately than any other known factor and that 80% of
biopsies provided enough material to generate an acceptable
molecular signature, despite the fact that the material was formalin
fixed and more than 10 years old. For this study, 2–4mm linear
segments of tumour material were excised from the paraffin-
embedded biopsy, which is not a routine procedure. Ongoing
studies are using up to ten multiple sections from the tumour
material. Based on limited experience, we have found that this
procedure in contemporary biopsy specimens yields enough
quality RNA to generate acceptable test results, but more empirical
data are needed.
Based on exploratory analyses presented here, there is evidence
that the CCP score may have a non-linear impact on the predicted
probability of prostate cancer death. This could either be due to a
true non-linear relationship between the CCP score and risk of
death from prostate cancer, or a lack of proportional hazards in
that the CCP score is a better predictor of earlier deaths. Although
the data set is not large enough to distinguish between these two
possibilities, we think that the latter is likely to be at least a partial
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Figure 2 Ten-year predicted risk of prostate cancer death according to
combined risk score, and a histogram of the combined score in different
Gleason score categories. Different categories are shown by different
coloured bars: blue, Gleason score o7; orange, Gleason score¼ 7; red,
Gleason score 47.
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Figure 3 Hazard ratio for prostate cancer mortality for a one-unit
change in CCP score for different clinical subgroups. The area of the box is
proportional to number of events in each group, and the horizontal bars
represent 95% confidence intervals (CI).
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Figure 4 Scatter plot of predicted 10-year risk of death from prostate
cancer for combined risk score vs clinical risk score. Different Gleason score
categories are shown by different coloured dots: (blue, Gleason o 7;
orange, Gleason¼ 7; red, Gleason47), whereas the vertical axis indicates
the added information in PSA and the horizontal axis for PSA and CCP
score. For any given patient, the added contribution of the CCP score to
the predicted risk, based on Gleason and PSA, can be determined by the
horizontal distance between the dot and the diagonal dashed line.
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explanation for two reasons. First, time-dependent effects are
commonly seen with prognostic markers (Fentiman et al, 1984).
Second, we see evidence for time dependence for CCP score in this
study and in a retrospective analysis of our TURP cohort (data not
shown). If confirmed, these data suggest it may be useful to retest
cancer found in subsequent needle biopsy specimens, especially if
other factors such as PSA suggest progression, to determine
appropriate management. Unfortunately, no follow-up biopsy
specimens were available for this study.
Misclassification of cause of death is a concern, but this will
generally weaken any real association of CCP score with prostate
cancer death. As a check, we evaluated the predictive value of the
risk factors, considered in this paper, for death from other causes
(censoring at death from prostate cancer). Only age was a strong
predictor, and none of the known factors for prostate cancer death
nor CCP score were significant at the 1% level.
Here, in contrast to our previous studies, we see a trend towards
a larger effect in patients with Gleason score greater than 7.
Although this trend was not significant, if confirmed, it suggests
that the CCP score may help stratify high-risk localised prostate
cancers into a favourable group that could be treated with local
therapy only vs an unfavourable group, more likely to develop
metastases quickly, whose survival could be improved with early
adjuvant systemic chemohormonal therapy, a question under
study in current clinical trials (e.g. NCT00430183).
The most obvious clinical use of the CCP score is to help identify
low-risk patients who can be safely managed by surveillance. In
this series, we were unable to identify a clinically significant
subgroup with a 10-year risk of dying from prostate cancer of less
than 5%. However, the CCP score increased the ability to identify
men with a less than 10% risk of dying from prostate cancer within
10 years, from 7 to 14%. In addition, for patients with a Gleason
score of 6, where considerable uncertainty still exists as to
appropriate treatment, the predicted 10-year prostate cancer death
rate with the addition of the CCP score ranged from 3.5 to 41.0%
(compared with 5.1 to 20.9% using clinical parameters only). We
believe this is relevant information when considering appropriate
care. However, as deaths from prostate cancer are rare in this
group, larger cohorts are needed to fully characterise the value of
the CCP score in identifying very low-risk patients, and a clearer
relationship may emerge when more patients have been studied.
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